The aim of Casc8 is to provide patients suffering from heart failure with an autologous batch of ‘in vitro’ expanded cardiac progenitor cells in order to regenerate the lost cardiac tissue. Thusfar, attempts to regenerate lost cardiac tissue have remained elusive. Contemporary drugs and interventions are not able to reverse decreased heart function and progression to heart failure in the infarct patients.
Casc8 wants to introduce the first successful treatment, based on generation of new cardiac tissue worldwide.

The founder of Casc8 is prof. Dr. Marc Hendrikx, a cardiothoracic surgeon at the AZ Damiaan in Oostende and connected to the BioMed Institute at UHasselt.